{"doi":"10.1002/acn3.51016","title":"Self‐reported rates of impulsivity in Parkinson’s Disease","abstract":"OBJECTIVE: Impulsive decision-making is characterized by actions taken without considering consequences. Patients with Parkinson's disease (PD) who receive dopaminergic treatment, especially dopamine agonists, are at risk of developing impulsive-compulsive behaviors (ICBs). We assessed impulse-related changes across a large heterogeneous PD population using the Barratt impulsivity scale (BIS-11) by evaluating BIS-11 first- and second-order factors. METHODS: We assessed a total of 204 subjects: 93 healthy controls (HCs), and 68 ICB- and 43 ICB + PD patients who completed the BIS-11. Using a general linear model and a least absolute shrinkage and selection operation regression, we compared BIS-11 scores between the HC, ICB- PD, and ICB + PD groups. RESULTS: Patients with PD rated themselves as more impulsive than HCs in the BIS-11 total score, second-order attention domain, and first-order attention and self-control domains. ICB + patients recorded higher total scores as well as higher scores in the second-order non-planning domain and in self-control and cognitive complexity than ICB- patients. INTERPRETATION: These results indicate that the patients with PD show particular problems with attentional control, whereas ICB + patients show a distinct problem in cognitive control and complexity. Additionally, it appears that all patients with PD are more impulsive than their age- and sex-matched healthy peers. Increased impulsivity may be a result of the disease course, or attributed to dopaminergic medication use, but these results emphasize the importance of the cognitive components of impulsivity in patients with PD.","journal":"Annals of Clinical and Translational Neurology","year":2020,"id":79324,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":16,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9631,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":412014,"name":"Adam Stark","orcid":"0000-0002-7543-9435","position":1,"is_corresponding":false},{"id":412015,"name":"Shelby Hughes","orcid":"0000-0002-4351-842X","position":2,"is_corresponding":false},{"id":412016,"name":"Ya‐Chen Lin","orcid":"0000-0003-3660-4570","position":3,"is_corresponding":false},{"id":274458,"name":"Hakmook Kang","orcid":"0000-0001-6876-4021","position":4,"is_corresponding":false},{"id":412897,"name":"Elise B. Bradley","orcid":null,"position":5,"is_corresponding":false},{"id":412017,"name":"David H. Zald","orcid":"0000-0002-1229-2923","position":6,"is_corresponding":false},{"id":388676,"name":"Daniel O. Claassen","orcid":"0000-0002-9853-4902","position":7,"is_corresponding":false},{"id":412013,"name":"Megan Aumann","orcid":"0000-0002-3924-8455","position":0,"is_corresponding":true}],"reference_count":79,"raw_metadata":null,"created_at":"2026-07-18T21:50:33.748601Z","pmid":"32227451","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}